Literature DB >> 3760277

Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations.

L R Espinoza, C G Espinoza, F B Vasey, B F Germain.   

Abstract

Eight patients with long-standing rheumatoid arthritis and cutaneous vasculitis ulcerations resistant to conventional therapy were treated successfully with a low-dose intermittent regimen of oral methotrexate. Objective clinical response was prompt and complete resolution was observed at about 12 weeks of therapy. The drug was well tolerated. Mild gastrointestinal side effects were the most common untoward reaction. We conclude that methotrexate therapy is an effective agent for some of the extraarticular manifestations of rheumatoid arthritis including vasculitis, and further clinical evaluation should be a consideration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3760277     DOI: 10.1016/s0190-9622(86)70202-8

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  Vasculitides throughout history and their clinical treatment today.

Authors:  Antonio Iglesias-Gamarra; Edgar Penaranda; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2011-12       Impact factor: 4.592

2.  Eruption of nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis.

Authors:  M E Jeurissen; A M Boerbooms; L B van de Putte
Journal:  Clin Rheumatol       Date:  1989-09       Impact factor: 2.980

Review 3.  Rheumatoid vasculitis: vanishing menace or target for new treatments?

Authors:  Christie M Bartels; Alan J Bridges
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

Review 4.  Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.

Authors:  R Luqmani; C Gordon; P Bacon
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 5.  Localized Forms of Vasculitis.

Authors:  Joana Martins-Martinho; Eduardo Dourado; Nikita Khmelinskii; Pablo Espinosa; Cristina Ponte
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.